Risk factors for OS, EFS, and NRM
| Variable (risk) . | Number under risk . | Univariate log-rank test: P . | Cox regression . | ||
|---|---|---|---|---|---|
| Hazard ratio . | 95% CI . | P . | |||
| OS | |||||
| Male sex | 30 | .242 | — | — | — |
| Age 60 y or more | 10 | .371 | — | — | — |
| No CR before HCT | 33 | .536 | — | — | — |
| No FL | 17 | .038 | 4.0 | 1.3-11.7 | .013 |
| Less than 3 cycles of chemotherapy | 8 | .195 | — | — | — |
| Duration of disease 2 y or more | 31 | .566 | — | — | — |
| Autologous HCT | 22 | .762 | — | — | — |
| Limited/extensive cGVHD | 19 | .004 | 0.3 | 0.1-0.8 | .022 |
| Acute GVHD 3 or more | 7 | .001 | 3.0 | 0.9-9.8 | .062 |
| Unrelated donor | 27 | .303 | — | — | — |
| Bulky disease | 7 | .844 | — | — | — |
| EFS | |||||
| Male sex | 30 | .237 | — | — | — |
| Age 60 y or more | 10 | .364 | — | — | — |
| No CR before HCT | 33 | .931 | — | — | — |
| No FL | 17 | .013 | 4.5 | 1.4-14.8 | .013 |
| Less than 3 cycles of chemotherapy | 8 | .150 | — | — | — |
| Duration of disease 2 y or more | 31 | .332 | — | — | — |
| Autologous HCT | 22 | .816 | — | — | — |
| Limited/extensive cGVHD | 19 | .001 | 0.3 | 0.1-1.2 | .096 |
| Acute GVHD 3 or more | 7 | .004 | 4.3 | 1.2-15.5 | .026 |
| Unrelated donor | 27 | .237 | — | — | — |
| Bulky disease | 7 | .476 | — | — | — |
| NRM | |||||
| Male sex | 30 | .359 | — | — | — |
| Age 60 y or more | 10 | .517 | — | — | — |
| No CR before HCT | 33 | .392 | — | — | — |
| No FL | 17 | .029 | 4.2 | 1.3-13.8 | .019 |
| Less than 3 cycles of chemotherapy | 8 | .110 | — | — | — |
| Duration of disease 2 y or more | 31 | .742 | — | — | — |
| Autologous HCT | 22 | .887 | — | — | — |
| Limited/extensive cGVHD | 19 | .016 | 0.4 | 0.1-1.4 | .141 |
| Acute GVHD 3 or more | 7 | < .001 | 3.9 | 1.1-14.2 | .041 |
| Unrelated donor | 27 | .073 | 1.9 | 0.4-9.0 | .429 |
| Bulky disease | 7 | .545 | — | — | — |
| Variable (risk) . | Number under risk . | Univariate log-rank test: P . | Cox regression . | ||
|---|---|---|---|---|---|
| Hazard ratio . | 95% CI . | P . | |||
| OS | |||||
| Male sex | 30 | .242 | — | — | — |
| Age 60 y or more | 10 | .371 | — | — | — |
| No CR before HCT | 33 | .536 | — | — | — |
| No FL | 17 | .038 | 4.0 | 1.3-11.7 | .013 |
| Less than 3 cycles of chemotherapy | 8 | .195 | — | — | — |
| Duration of disease 2 y or more | 31 | .566 | — | — | — |
| Autologous HCT | 22 | .762 | — | — | — |
| Limited/extensive cGVHD | 19 | .004 | 0.3 | 0.1-0.8 | .022 |
| Acute GVHD 3 or more | 7 | .001 | 3.0 | 0.9-9.8 | .062 |
| Unrelated donor | 27 | .303 | — | — | — |
| Bulky disease | 7 | .844 | — | — | — |
| EFS | |||||
| Male sex | 30 | .237 | — | — | — |
| Age 60 y or more | 10 | .364 | — | — | — |
| No CR before HCT | 33 | .931 | — | — | — |
| No FL | 17 | .013 | 4.5 | 1.4-14.8 | .013 |
| Less than 3 cycles of chemotherapy | 8 | .150 | — | — | — |
| Duration of disease 2 y or more | 31 | .332 | — | — | — |
| Autologous HCT | 22 | .816 | — | — | — |
| Limited/extensive cGVHD | 19 | .001 | 0.3 | 0.1-1.2 | .096 |
| Acute GVHD 3 or more | 7 | .004 | 4.3 | 1.2-15.5 | .026 |
| Unrelated donor | 27 | .237 | — | — | — |
| Bulky disease | 7 | .476 | — | — | — |
| NRM | |||||
| Male sex | 30 | .359 | — | — | — |
| Age 60 y or more | 10 | .517 | — | — | — |
| No CR before HCT | 33 | .392 | — | — | — |
| No FL | 17 | .029 | 4.2 | 1.3-13.8 | .019 |
| Less than 3 cycles of chemotherapy | 8 | .110 | — | — | — |
| Duration of disease 2 y or more | 31 | .742 | — | — | — |
| Autologous HCT | 22 | .887 | — | — | — |
| Limited/extensive cGVHD | 19 | .016 | 0.4 | 0.1-1.4 | .141 |
| Acute GVHD 3 or more | 7 | < .001 | 3.9 | 1.1-14.2 | .041 |
| Unrelated donor | 27 | .073 | 1.9 | 0.4-9.0 | .429 |
| Bulky disease | 7 | .545 | — | — | — |
— indicates not applicable.